Brokerages Set Chemed Corporation (NYSE:CHE) Target Price at $574.25

Shares of Chemed Corporation (NYSE:CHE) have earned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $574.25.

Several equities analysts recently issued reports on the stock. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a report on Thursday, October 30th. Oppenheimer cut their target price on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a research note on Thursday, July 31st. Royal Bank Of Canada decreased their price target on Chemed from $589.00 to $572.00 and set an “outperform” rating on the stock in a research report on Monday, November 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Chemed in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group upgraded Chemed from a “hold” rating to a “buy” rating and increased their target price for the stock from $490.00 to $550.00 in a report on Tuesday, September 2nd.

Chemed Trading Down 1.1%

CHE stock opened at $436.81 on Friday. Chemed has a 1-year low of $408.42 and a 1-year high of $623.60. The business’s 50 day moving average is $441.60 and its 200-day moving average is $476.92. The firm has a market cap of $6.19 billion, a P/E ratio of 23.10, a P/E/G ratio of 2.69 and a beta of 0.43.

Chemed (NYSE:CHE) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $5.27 EPS for the quarter, missing the consensus estimate of $5.39 by ($0.12). Chemed had a net margin of 11.02% and a return on equity of 25.89%. The company had revenue of $624.90 million during the quarter, compared to analyst estimates of $626.04 million. During the same period in the prior year, the firm earned $5.64 EPS. Chemed’s quarterly revenue was up 3.1% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. Sell-side analysts forecast that Chemed will post 21.43 EPS for the current year.

Chemed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Monday, November 17th will be issued a dividend of $0.60 per share. The ex-dividend date of this dividend is Monday, November 17th. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. Chemed’s dividend payout ratio is currently 12.69%.

Insider Activity

In other news, CEO Kevin J. Mcnamara sold 3,000 shares of the stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $461.28, for a total transaction of $1,383,840.00. Following the sale, the chief executive officer directly owned 96,197 shares of the company’s stock, valued at $44,373,752.16. This represents a 3.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Patrick P. Grace sold 150 shares of the business’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total transaction of $69,508.50. Following the completion of the transaction, the director owned 3,397 shares of the company’s stock, valued at $1,574,135.83. This trade represents a 4.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 3.29% of the company’s stock.

Institutional Investors Weigh In On Chemed

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Jump Financial LLC acquired a new position in Chemed in the first quarter valued at approximately $2,777,000. Commerce Bank lifted its stake in shares of Chemed by 246.6% in the 1st quarter. Commerce Bank now owns 5,216 shares of the company’s stock valued at $3,210,000 after purchasing an additional 3,711 shares during the period. Synovus Financial Corp boosted its position in shares of Chemed by 47.9% in the 1st quarter. Synovus Financial Corp now owns 1,827 shares of the company’s stock worth $1,124,000 after purchasing an additional 592 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new stake in shares of Chemed during the second quarter worth $342,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Chemed during the first quarter worth $891,000. Institutional investors own 95.85% of the company’s stock.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.